Cargando…

Cycloastragenol Attenuates Osteoclastogenesis and Bone Loss by Targeting RANKL-Induced Nrf2/Keap1/ARE, NF-κB, Calcium, and NFATc1 Pathways

Osteoporosis, which typically affects postmenopausal women, is an osteolytic disease due to over-activation of osteoclasts. However, current drugs targeting osteoclast inhibition face various side effects, making natural compounds with great interest as alternative treatment options. Cycloastragenol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Gang, Ma, Chao, Chen, Kai, Wang, Ziyi, Qiu, Heng, Chen, Delong, He, Jianbo, Zhang, Cheng, Guo, Ding, Lai, Boyong, Zhang, Shuangxiao, Huang, Linfeng, Yang, Fan, Yuan, Jinbo, Chen, Leilei, He, Wei, Xu, Jiake
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812338/ https://www.ncbi.nlm.nih.gov/pubmed/35126144 http://dx.doi.org/10.3389/fphar.2021.810322

Ejemplares similares

Dracorhodin perchlorate inhibits osteoclastogenesis through repressing RANKL‐stimulated NFATc1 activity
por: Liu, Yuhao, et al.
Publicado: (2020)

Cytochalasin Z11 inhibits RANKL-induced osteoclastogenesis via suppressing NFATc1 activation
por: Wang, Lu, et al.
Publicado: (2019)

Inhibitory Effects of Rhaponticin on Osteoclast Formation and Resorption by Targeting RANKL-Induced NFATc1 and ROS Activity
por: He, Jianbo, et al.
Publicado: (2021)

Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities
por: Liu, Yuhao, et al.
Publicado: (2019)

Maackiain dampens osteoclastogenesis via attenuating RANKL‐stimulated NF‐κB signalling pathway and NFATc1 activity
por: Liu, Yuhao, et al.
Publicado: (2020)

Asiatic Acid Inhibits OVX-Induced Osteoporosis and Osteoclastogenesis Via Regulating RANKL-Mediated NF-κb and Nfatc1 Signaling Pathways
por: Hong, Guoju, et al.
Publicado: (2020)

Adseverin mediates RANKL-induced osteoclastogenesis by regulating NFATc1
por: Song, Min-Kyoung, et al.
Publicado: (2015)

12-Deoxyphorbol-13-Hexadecanoate Abrogates OVX-Induced Bone Loss in Mice and Osteoclastogenesis via Inhibiting ROS Level and Regulating RANKL-Mediated NFATc1 Activation
por: He, Qi, et al.
Publicado: (2022)

Betulinic Acid Protects From Bone Loss in Ovariectomized Mice and Suppresses RANKL-Associated Osteoclastogenesis by Inhibiting the MAPK and NFATc1 Pathways
por: Wei, Jiyong, et al.
Publicado: (2020)

TGFβ1 Regulates Human RANKL-Induced Osteoclastogenesis via Suppression of NFATc1 Expression
por: Tokunaga, Tadahiro, et al.
Publicado: (2020)

Peiminine Suppresses RANKL-Induced Osteoclastogenesis by Inhibiting the NFATc1, ERK, and NF-κB Signaling Pathways
por: Zhu, Mengbo, et al.
Publicado: (2021)

STIM1 controls calcineurin/Akt/mTOR/NFATC2-mediated osteoclastogenesis induced by RANKL/M-CSF
por: Huang, Yanjiao, et al.
Publicado: (2020)

Madecassoside inhibits estrogen deficiency‐induced osteoporosis by suppressing RANKL‐induced osteoclastogenesis
por: Wang, Qingqing, et al.
Publicado: (2018)

Angelica sinensis extract inhibits RANKL-mediated osteoclastogenesis by down-regulated the expression of NFATc1 in mouse bone marrow cells
por: Kong, Lingbo, et al.
Publicado: (2014)

Agelasine D Suppresses RANKL-Induced Osteoclastogenesis via Down-Regulation of c-Fos, NFATc1 and NF-κB
por: Kang, Moo Rim, et al.
Publicado: (2014)

Anemonin Attenuates RANKL-Induced Osteoclastogenesis and Ameliorates LPS-Induced Inflammatory Bone Loss in Mice via Modulation of NFATc1
por: Hou, Huanhuan, et al.
Publicado: (2020)

Evodiamine inhibits RANKL‐induced osteoclastogenesis and prevents ovariectomy‐induced bone loss in mice
por: Jin, Haiming, et al.
Publicado: (2018)

Umbelliferone Prevents Lipopolysaccharide-Induced Bone Loss and Suppresses RANKL-Induced Osteoclastogenesis by Attenuating Akt-c-Fos-NFATc1 Signaling
por: Kwak, Sung Chul, et al.
Publicado: (2019)

Astilbin prevents bone loss in ovariectomized mice through the inhibition of RANKL‐induced osteoclastogenesis
por: Jin, Haiming, et al.
Publicado: (2019)

Dehydrocostus lactone inhibits NFATc1 via regulation of IKK, JNK, and Nrf2, thereby attenuating osteoclastogenesis
por: Lee, Hye In, et al.
Publicado: (2020)

Asperpyrone A attenuates RANKL‐induced osteoclast formation through inhibiting NFATc1, Ca(2+) signalling and oxidative stress
por: Chen, Xi, et al.
Publicado: (2019)

KMUP-1 Suppresses RANKL-Induced Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss: Roles of MAPKs, Akt, NF-κB and Calcium/Calcineurin/NFATc1 Pathways
por: Liou, Shu-Fen, et al.
Publicado: (2013)

Disulfiram suppressed ethanol promoted RANKL-induced osteoclastogenesis in vitro and ethanol-induced osteoporosis in vivo via ALDH1A1-NFATc1 axis
por: Jia, Yewei, et al.
Publicado: (2019)

Vindoline Inhibits RANKL-Induced Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss in Mice
por: Zhan, Yunfei, et al.
Publicado: (2020)

The deubiquitinase UCHL1 negatively controls osteoclastogenesis by regulating TAZ/NFATC1 signalling
por: Feng, Zhenhua, et al.
Publicado: (2023)

Rosiglitazone suppresses RANKL‐induced NFATc1 autoamplification by disrupting the physical interaction between NFATc1 and PPARγ
por: Park, Kyeong‐Lok, et al.
Publicado: (2018)

Parthenolide inhibits osteoclast differentiation and bone resorbing activity by down-regulation of NFATc1 induction and c-Fos stability, during RANKL-mediated osteoclastogenesis
por: Kim, Ju-Young, et al.
Publicado: (2014)

C-phycocyanin attenuates RANKL-induced osteoclastogenesis and bone resorption in vitro through inhibiting ROS levels, NFATc1 and NF-κB activation
por: AlQranei, Mohammed S., et al.
Publicado: (2020)

Inhibition of RANKL-Induced Osteoclastogenesis by Novel Mutant RANKL
por: Jang, Yuria, et al.
Publicado: (2021)

Gα12 regulates osteoclastogenesis by modulating NFATc1 expression
por: Song, Min‐Kyoung, et al.
Publicado: (2017)

The Role of Ca(2+)-NFATc1 Signaling and Its Modulation on Osteoclastogenesis
por: Kang, Jung Yun, et al.
Publicado: (2020)

Dectin-1 signaling inhibits osteoclastogenesis via IL-33-induced inhibition of NFATc1
por: Zhu, Xiaoqing, et al.
Publicado: (2017)

Transforming growth factor-β enables NFATc1 expression during osteoclastogenesis
por: Fox, S.W., et al.
Publicado: (2008)

Accelerated Lactate Dehydrogenase Activity Potentiates Osteoclastogenesis via NFATc1 Signaling
por: Ahn, Heejin, et al.
Publicado: (2016)

A novel RANKL‐targeted flavonoid glycoside prevents osteoporosis through inhibiting NFATc1 and reactive oxygen species
por: Hong, Guoju, et al.
Publicado: (2021)

Mitf Induction by RANKL Is Critical for Osteoclastogenesis
por: Lu, Ssu-Yi, et al.
Publicado: (2010)

NF-κB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor
por: Kubota, Tetsuo, et al.
Publicado: (2007)

Melatonin Attenuates RANKL-Induced Osteoclastogenesis via Inhibition of Atp6v0d2 and DC-STAMP through MAPK and NFATc1 Signaling Pathways
por: Kim, Seong-Sik, et al.
Publicado: (2022)

BHLHE40 promotes osteoclastogenesis and abnormal bone resorption via c-Fos/NFATc1
por: Zhang, Yufeng, et al.
Publicado: (2022)

Sesamolin Protects Mice From Ovariectomized Bone Loss by Inhibiting Osteoclastogenesis and RANKL-Mediated NF-κB and MAPK Signaling Pathways
por: Yang, Xue, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_urqucnj79ttvrdf8ap2smc3eb4